
Please try another search
Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark.
Name | Age | Since | Title |
---|---|---|---|
Gunnar Magnus Severus Modee Persson | 62 | 2016 | Chairman of the Board of Directors |
Claus Elsborg Olesen | 48 | 2016 | Co-Founder, CEO & Director |
Peter Joakim Holm | 51 | 2016 | Director |
Sue Goldstein | - | 2020 | Member of Scientific & Clinical Advisory Board |
Irwin Goldstein | - | 2020 | Member of Scientific & Clinical Advisory Board |
Annette Ingegerd Colin | 60 | 2021 | Director |
Gunilla Ekstrom | 67 | 2022 | Independent Director |
Goran Ando | 76 | 2025 | Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review